创新药物制剂研发

ShanghaiInstituteofMateriaMedica,ChineseAcademyof ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof22ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof33成本高成本高：16亿美金/周期长：10年~15成功率低ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof 药物制 ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof生理因

ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof

PorterPorteretal.ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof类已类已批准上全球在 口服制剂BCS分类情

Lipinski“5” 和 和 ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof放弃重来，改造化合物结。8ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof制剂制剂技术应 JosephG.Lombardinoetal.Naturereviewsdrug ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof

増药量药ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof解离脂溶稳解离脂溶稳定ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof一、解离药物的存在状态受pKa与pH共同影ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyofShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof二、脂溶数药物脂溶性↑ 吸收ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof三、溶出速药物溶出理论：药物与溶剂间的>固体药dC/dt=sShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof

SS效剂量多晶

溶剂化ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof四、稳定增加药物在胃肠道中稳定性段：包衣、制ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyofShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof发现阶段制 的技术要目的：增溶或提高透膜微量 ：毫克级别；载药量低（多高通 ：快 、稳定 临 •Ⅰ期临床研研 •Ⅱ期临床研Ⅲ期临床研创 •候选药物质量控制、剂型研药 •候选药物毒性研开候选药物疗效研 •候选化合物生物活性研究发 •候选化合物药理毒理研候选药候选药药理毒药稳定杂质控其他质量指

制剂技制剂技提高生物利用临床药高低良好的患者体基于专利的考剂型（人用化ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof生物药剂学分类系统与剂型设类溶解渗透限速过制剂设计重制剂策Ⅰ高高Ⅱ低高Ⅲ高低Ⅳ低低ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyofShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof

ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof增加增加平衡溶解（热力学方法增溶辅料用量

更高游离药物浓增溶辅料用量ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof热熔热熔挤出固体高载高载药纳米晶ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyofShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof提高透膜能TranscellularApical Apical Efflux

CC CDBasolateral

Paracellular

ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyofShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof实新化合物X的制剂研处方处方前信水中溶解度LogP～存在问量低，药效安评试验中存在收饱和 量极低药物无毒性反量晶型A量晶型A﹥晶型制剂研究：晶型A可増溶能力﹥晶型制剂规制剂规格10mg/ml（溶解度增加1000倍以上大鼠体内绝对生物利用度由混悬剂5.5%增至小鼠体内有效剂量由15mg/kg降至利用国内外先进的热熔挤出技 固体分散ShanghaiShanghaiInstituteofMateriaMedica,ChineseAcademyof制剂规格食物效应对化合物X饱腹吸收优于空腹（相对F值片剂犬体内绝对生物利用度由混悬剂1.7% ShanghaiShanghaiInstituteofMateriaMed